Back to Research Hub
Ionis Pharmaceuticals, Inc.
IONS
$74.58+1.04 (+1.41%)
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and…
StreetsValue research for Ionis Pharmaceuticals, Inc. (IONS)
Members get the full report for Ionis Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.